Safety of MR liver specific contrast media.
Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.
Bellin
Marie-France
MF
Université Paris 11, AP-HP, Service de Radiologie, Hôpital Paul Brousse, 12-14 avenue Paul Vaillant Couturier, 94804, Villejuif Cedex, France.
Webb
Judith A W
JA
Van Der Molen
Aart J
AJ
Thomsen
Henrik S
HS
Morcos
Sameh K
SK
D001660:Biliary Tract Diseases / Q000175:diagnosis; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D052203:Ferrosoferric Oxide; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D007501:Iron / Q000009:adverse effects; D008099:Liver / Q000033:anatomy & histology* / Q000187:drug effects; D008107:Liver Diseases / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008345:Manganese / Q000009:adverse effects; D010087:Oxides / Q000009:adverse effects
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D008345:Manganese; D005682:Gadolinium; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide